Plain-English translation of NCT05552755 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing a new medication called to see if it can help slow or reduce the growth of polyps in people with familial adenomatous polyposis (FAP). FAP is a genetic condition where hundreds of polyps grow in the digestive tract, and this medication aims to help control them. The study will measure how safe the medication is, how well it works, and how your body processes it.
People with FAP face a high risk of cancer because of all the polyps in their digestive tract, even after surgery to remove parts of the colon. This trial exists to find out whether this new treatment can help reduce polyp growth and potentially lower cancer risk, offering patients a better option than managing polyps through repeated procedures alone.
You likely qualify if…
You likely don't qualify if…
The study has two parts. In Part 1, you will receive either a placebo or the medication in a single dose, wait 2–4 weeks, then take daily doses for 2 weeks while your heart function and blood work are monitored. In Part 2, you will take the medication daily for 12 weeks followed by a 12-week break, or take it on a 7-days-on, 7-days-off schedule for 24 weeks. You will have regular clinic visits for blood tests, heart monitoring, and endoscopy procedures to check your polyp growth.
AI-generated summary from trial data · Aug 14, 2026 · Not medical advice
United States